France
www.yvesrocher.com
Sales: $1.4 billion (estimated)
Key Personnel:
Bris Rocher, chief executive officer and chairman of the board of directors of the Group Yves Rocher; Stéphane Bianchi, chief executive officer of the Group Yves Rocher; Claude Fromageot, research and development director; Jean-Michel Boisserand, director of Internet stores and France; Laurent Marchal, chief executive officer of Yves Rocher North America Inc.; Elise Rebut, biodiversity manager; Jacques Rocher, president, Yves Rocher Foundation.
Major Products:
Skin care, cosmetics and fine fragrances marketed under the brand names of Yves Rocher, Dr. Pierre Ricaud, Stanhome, Kiotis and Daniel Jouvance.
New Products:
Elixir 7.9, 3 Detoxifying Teas cleansing care, Ovale Lifting anti-aging line for women over 45, Comme une Evidence Homme Green eau de toilette, Botanical Hair Care , Moment de Bonheur eau de parfum, Couleurs Nature Mix&Match, New Culture Bio products—Lifting Bio.
Comments:
Yves Rocher sells more than 300 million products a year in 80 countries. The group is family-owned with more than 75% owned by several generations of what officials call “entrepreneurs-creators.”
According to Kline Group, the company’s 2010 sales were $1.4 billion.
Events of note during the past year include the opening of its first store and franchise in Novia Scotia (June 2010) and a $5 million investment in the company’s Cork, Ireland facility. Yves Rocher came to Cork in 1981 and established its current facility in 1984. The site exported 66 million units of high quality skin care products in 2010 and that figure is projected to grow to 88 million units by 2015, according to sources.
On the new products front, Yves Rocher has rolled out Exilir 7.9, a serum that reportedly doubles the effectiveness of any anti-aging skin care product with seven active botanicals and nine anti-aging patents. The lucky seven include apple oligosides (three patents), acacia polyosides (one patent), green rice inositol (one patent), tara galactosides (one patent), aloe vera polyosides (one patent), aphloia mangiferin (one patent), and beet betaine (one patent).
